Close Menu

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Aptiv Solutions today announced a partnership with Cancer Genetics for products and services directed at oncology clinical trials.

The two firms did not specify what products or services will result from the deal, but Aptiv said in a statement that they will provide "biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role of biomarkers in the oncology drug development process."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.